- Home
- ATXS vs ABSI Comparison
ATXS vs ABSI Comparison
Compare ATXS & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- ABSI
- Stock Information
- Founded
- ATXS 2008
- ABSI 2011
- Country
- ATXS United States
- ABSI United States
- Employees
- ATXS N/A
- ABSI N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- ABSI Biotechnology: Pharmaceutical Preparations
- Sector
- ATXS Health Care
- ABSI Health Care
- Exchange
- ATXS Nasdaq
- ABSI Nasdaq
- Market Cap
- ATXS 401.2M
- ABSI 338.0M
- IPO Year
- ATXS 2015
- ABSI 2021
- Fundamental
- Price
- ATXS $6.85
- ABSI $2.93
- Analyst Decision
- ATXS Buy
- ABSI Strong Buy
- Analyst Count
- ATXS 6
- ABSI 5
- Target Price
- ATXS $32.00
- ABSI $8.08
- AVG Volume (30 Days)
- ATXS 248.4K
- ABSI 6.8M
- Earning Date
- ATXS 08-12-2025
- ABSI 08-12-2025
- Dividend Yield
- ATXS N/A
- ABSI N/A
- EPS Growth
- ATXS N/A
- ABSI N/A
- EPS
- ATXS N/A
- ABSI N/A
- Revenue
- ATXS N/A
- ABSI $4,138,000.00
- Revenue This Year
- ATXS N/A
- ABSI $74.53
- Revenue Next Year
- ATXS N/A
- ABSI $296.01
- P/E Ratio
- ATXS N/A
- ABSI N/A
- Revenue Growth
- ATXS N/A
- ABSI 27.32
- 52 Week Low
- ATXS $3.56
- ABSI $2.01
- 52 Week High
- ATXS $12.92
- ABSI $6.33
- Technical
- Relative Strength Index (RSI)
- ATXS 56.47
- ABSI 49.27
- Support Level
- ATXS $6.60
- ABSI $2.80
- Resistance Level
- ATXS $7.20
- ABSI $3.40
- Average True Range (ATR)
- ATXS 0.47
- ABSI 0.21
- MACD
- ATXS -0.03
- ABSI -0.01
- Stochastic Oscillator
- ATXS 61.72
- ABSI 28.79
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.